Last reviewed · How we verify
NCT03935308: MRgRTPCa
Phase I Study MR-guided SBRT to PCa
NA trial testing MR guided Linear Accelerator in Low or Intermediate Risk Prostate Cancer. Withdrawn.
31 December 2021
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 23 April 2019 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MR guided Linear Accelerator
Conditions studied
- Low or Intermediate Risk Prostate Cancer — all drugs for Low or Intermediate Risk Prostate Cancer →
Sponsor
Henry Ford Health System — full company profile →
Who can join
18 and older, male only, with Low or Intermediate Risk Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1\) investigate the feasibility, tolerance, and safety of dose escalation via MR-guided stereotactic body radiation therapy and simultaneous integrated boost to the dominant intraprostatic lesions (DILs), 2) to assess the feasibility of DIL visualization based on multi-parametric MRI (mpMRI), and 3) to characterize longitudinal changes in imaging characteristics and identify urinary biomarkers for treatment response prediction
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM, Lamb JM, Casado M, Wang X, et al · · 2021 · cited 33× · PMID 33975579 · DOI 10.1186/s12885-021-08281-x -
Stereotactic Body Radiotherapy for Prostate Cancer.
Parikh NR, Kishan AU. · · 2020 · cited 12× · PMID 32500805 · DOI 10.1177/1557988320927241
Verify or expand the search:
- PubMed search for NCT03935308
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03935308 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 25 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03935308.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing